Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
feladilimab (GSK3359609)
i
Other names:
GSK3359609, GSK 3359609, GSK-3359609, inducible T-cell co-stimulator, GSK609
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
GSK
Drug class:
ICOS agonist
Related drugs:
‹
JTX-2011 (1)
BMS-986226 (0)
ICOSL vIgD (0)
SAR445256 (0)
JTX-2011 (1)
BMS-986226 (0)
ICOSL vIgD (0)
SAR445256 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
PD-1 expression
Urothelial Cancer
PD-1 expression
Urothelial Cancer
pembrolizumab + GSK3359609
Sensitive: C3 – Early Trials
pembrolizumab + GSK3359609
Sensitive
:
C3
pembrolizumab + GSK3359609
Sensitive: C3 – Early Trials
pembrolizumab + GSK3359609
Sensitive
:
C3
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + GSK3359609
Sensitive: C3 – Early Trials
pembrolizumab + GSK3359609
Sensitive
:
C3
pembrolizumab + GSK3359609
Sensitive: C3 – Early Trials
pembrolizumab + GSK3359609
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login